Skip to main content
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
User login
Username
Password
Reset your password
Concept
Lead
score
Non-Hodgkin Lymphoma (NHL)
1
1
Biologic Therapy
0
0.99
CAR-T
0
0.95
T-Lymphocyte
0
0.57
B-Cell Lymphoma
0
0.44
Lymphoma
0
0.4
Stem Cell Research and Therapy
0
0.33
Chemotherapy
0
0.23
Refractory
0
0.17
Cell Transplantation
0
0.12
Clinical Research
0
0.11
Genomic Medicine
0
0.11
Transplantation
0
0.11
Antigens
0
0.06
Cancer
0
0.06
CRISPR
0
0.06
Hematology
0
0.06
Imbalance
0
0.06
Platinum
0
0.06
Receptors
0
0.06
Salvage Therapy
0
0.06
Steroids
0
0.06
Specialty
Lead
score
Hematology-Oncology
1
1